drugset / Trial / NCT00376896

Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers

NCT00376896

Phase 1 Completed 25 enrolled GlaxoSmithKline
RandomizedCrossoverQuadruple-blindTreatment

Summary

This is a three-period crossover study to compare GW876008 and placebo to see if GW876008 will normalise blood flow responses after different emotional stimuli.

Timeline

Start
2006-11
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject EMICERFONT Small molecule 20 ug
Subject EMICERFONT Small molecule 200 ug